Nct03990233 1443 1 Inoncology вђ Boehringer Ingelheim A phase i, open label, dose escalation study of sirpα antagonist (bi 765063) with or without ezabenlimab (pd 1 inhibitor) in patients with advanced solid tumors (nct03990233) ae, adverse event; dlt, dose limiting toxicity; ecog ps, eastern cooperative oncology group performance status; mtd, maximum tolerated dose; orr, objective response rate. Nct03990233 (1443 0001) 4,11. i. bi 765063 ± ezabenlimab (pd 1 inhibitor) advanced solid tumors that have a sirpα polymorphism, including at least one v1 allele. completed recruitment. nct05249426 (1443 0002) 6. i. bi 765063 ± ezabenlimab (pd 1 inhibitor) alone or with bi 836880, chemotherapy, or cetuximab. recurrent metastatic hnscc or hcc.
Nct03990233 1443 0001 Inoncology вђ Boehringer Ingelheim Nct03990233 (1443.1) 1. bi 765063 ± ezabenlimab (pd 1 inhibitor) advanced solid tumors that have a sirpα polymorphism, including at least one v1 allele. completed recruitment. nct05249426 (1443.2) 1. bi 765063 ± ezabenlimab (pd 1 inhibitor) alone or with bi 836880, chemotherapy, or cetuximab. recurrent or metastatic hnscc or hcc. completed. The first in class, selective sirpα inhibitor bi 765063 in combination with the pd 1 inhibitor ezabenlimab was well tolerated with no dlts. one patient had grade 2 anaemia, but no other haemotoxic aes frequently associated with cd47 targeting therapies were reported. the rp2d of bi 765063 was 24 mg kg q3w with full ro saturation. In step 1, bi 765063 ascending doses, given iv every 3 weeks, were tested using a bayesian logistic regression model (blrm) approach with overdose control. the endpoints were safety, pharmacokinetics, receptor occupancy (ro) in peripheral cd14 monocytes and efficacy (recist 1.1). In a meta analysis evaluating the prognostic significance of cd47 in human malignancies, which included 38 cohorts with a total of 7,229 patients, authors found that the increased expression of cd47 correlated with decreased overall survival (pooled hr = 1.49: 95% ci: 1.36 1.62, p < 0.001) in patients with six different types of tumors . to the.
Nct05068102 1443 0003 Inoncology вђ Boehringer Ingelheim In step 1, bi 765063 ascending doses, given iv every 3 weeks, were tested using a bayesian logistic regression model (blrm) approach with overdose control. the endpoints were safety, pharmacokinetics, receptor occupancy (ro) in peripheral cd14 monocytes and efficacy (recist 1.1). In a meta analysis evaluating the prognostic significance of cd47 in human malignancies, which included 38 cohorts with a total of 7,229 patients, authors found that the increased expression of cd47 correlated with decreased overall survival (pooled hr = 1.49: 95% ci: 1.36 1.62, p < 0.001) in patients with six different types of tumors . to the. 1 low sirpαthreshold 0.75 0.5 0.25 0 0 10 20 30 40 p=0.023 22 14 8 2 0 22 7 0 0 0 number at risk sirpαin cd11b cells y high sirpαthreshold 1 low sirpαthreshold 0.75 0.5 0.25 0 0 10 20 30 40 time (weeks) p=0.098 22 14 7 1 0 22 7 1 1 0 number at risk sirpαin cd68 cells time (weeks) 1 0.75 0.5 0.25 0 y 0 10 20 30 40 p=0.47 22 10 3 1 0 22 11. The first clinical results were presented on the site of innovent as 20% orr (according to recistv1.1) and 74.1% treatment‐related ae that was mostly grade 1–2 anaemia. hx‐009 is another pd‐1 cd47 bispecific approach, in this case comprising a pd‐1 antibody fused to soluble sirpα, which is currently being evaluated in a clinical.
Comments are closed.